Head and neck cancer trials in Spain
52 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleLYSARI – LYmphocyte-Sparing And Radio-Immunotherapy in Head and neck carcinoma - A multicenter, randomised 2*2 factorial design comparing standard to reduced-target volume radiotherapy with or without all-trans retinoic acid (ATRA) in patients with lateralised oropharyngeal, laryngeal and hypopharyngeal squamous cell carcinoma.
- Where
- Badajoz, Barakaldo, Girona, L'Hospitalet de Llobregat, Málaga
- Age
- 18 years and over
- People
- 630 worldwide
- Run by
- Centre Leon Berard
See details and how to join2022-501315-13-00 · EU 2022-501315-13-00 - Phase 1Taking peopleA Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 540 worldwide
- Run by
- Pfizer
See details and how to joinNCT07090499 · EU 2025-521729-33-00 - Phase 1Taking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- L'Hospitalet de Llobregat, Madrid, Sevilla
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - Phase 3Taking peopleJNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
- Where
- Barakaldo, Barcelona, Jerez de la Frontera, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Lugo, Madrid, Málaga, Pamplona, Sabadell, Santander, Seville, Valencia, Zaragoza
- Age
- 60 years and over
- People
- 500 worldwide
- Run by
- Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT04892173 · EU 2024-520386-31-00 - Phase 1/2Taking peopleA Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid
- Age
- 18 years and over
- People
- 287 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06385080 · EU 2023-508418-40-00 - Phase 1Taking peopleA Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
- Where
- L'Hospitalet de Llobregat, Madrid, Valencia
- Age
- 18 years to 74 years
- People
- 45 worldwide
- Run by
- Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT07219212 · EU 2025-522914-22-00 - Phase 3Taking peopleA Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Santiago De Compostela, Valencia, Zaragoza
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07276399 · EU 2025-521917-24-00 - Phase 1/2Taking peopleA Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Where
- Barcelona, Madrid, Pamplona, Valencia
- Age
- 18 years and over
- People
- 560 worldwide
- Run by
- Genmab
See details and how to joinNCT03526835 · EU 2024-513627-16-01 - Phase 2/3Taking peopleFORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Where
- Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Santander, Valencia
- Age
- 18 years and over
- People
- 650 worldwide
- Run by
- Bicara Therapeutics
See details and how to joinNCT06788990 · EU 2024-519654-37-00 - Phase 2Taking peopleDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- A Coruña, Barcelona, Girona, L'Hospitalet de Llobregat, Logrono
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - Phase 2/3Taking peopleOrdastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
- Where
- A Coruña, Barcelona, Madrid, Pamplona, Santiago, Valencia
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Inhibrx Biosciences, Inc
See details and how to joinNCT06295731 - Phase 1/2Taking peopleA Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
- Where
- Barcelona, Madrid, Málaga, PAU de Sanchinarro, Pozuelo de Alarcón, Seville, Valencia
- Age
- 18 years and over
- People
- 235 worldwide
- Run by
- Alentis Therapeutics AG
See details and how to joinNCT06747585 · EU 2024-515459-39-00 - Phase 1/2Taking peopleA Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 248 worldwide
- Run by
- Terremoto Biosciences Inc.
See details and how to joinNCT07109726 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Barcelona, Madrid, Málaga, Seville, Valencia
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 1/2Taking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Sevilla
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - Phase 2Taking peopleA Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Where
- A Coruña, Barcelona, Madrid, Pamplona, Seville, Zaragoza
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06769698 · EU 2024-517620-19-00 - Phase 1Taking peopleAnti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 138 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07360314 · EU 2025-523232-39-00 - Phase 1Taking peopleStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Where
- Badalona, Barcelona, Madrid, Málaga, Pamplona, Zaragoza
- Age
- 18 years and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00 - Phase 2Taking peopleA Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
- Where
- Badalona, Madrid, Sevilla, Valencia, Zaragoza
- Age
- 18 years and over
- People
- 160 worldwide
- Run by
- Bicara Therapeutics
See details and how to joinNCT07807163 · EU 2026-526741-10-00 - Phase 3Taking peopleA Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
- Where
- Barcelona, Girona, Madrid, Seville, Valencia, Zaragoza
- Age
- 18 years and over
- People
- 260 worldwide
- Run by
- Corbus Pharmaceuticals Inc.
See details and how to joinNCT07768189 · EU 2026-527123-94-00 - Phase 1/2Taking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Barcelona, Madrid, Rioja, Valencia
- Age
- 12 years and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - Phase 1Taking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Badajoz, Barcelona, Madrid, Pamplona, Santander, Sevilla, Valencia
- Age
- 18 years and over
- People
- 1,394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - Phase 3Taking peopleA Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- Where
- Badalona, Barcelona, Jaén, Madrid, Valencia
- Age
- 18 years to 130 years
- People
- 1,145 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06129864 - Phase 1Taking peopleA Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Denikitug (GS-1811), an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti–PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors
- Where
- Barcelona, Madrid, Pamplona, Pozuelo de Alarcón
- Age
- 18 years and over
- People
- 93 worldwide
- Run by
- Gilead Sciences Inc.
See details and how to joinNCT05007782 · EU 2022-501684-40-00 - Phase 1Taking peopleEvaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Where
- Barcelona, Madrid, Piqueras, Seville
- Age
- 18 years and over
- People
- 540 worldwide
- Run by
- SystImmune Inc.
See details and how to joinNCT05983432